-
Article
Open AccessDianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells
1,2:5,6-Dianhydrogalactitol (DAG) is a bi-functional DNA-targeting agent currently in phase II clinical trial for treatment of temozolomide-resistant glioblastoma (GBM). In the present study, we investigated t...
-
Article
Open AccessDianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination
1,2:5,6-Dianhydrogalactitol (DAG) is a bifunctional DNA-targeting agent causing N7-guanine alkylation and inter-strand DNA crosslinks currently in clinical trial for treatment of glioblastoma. While preclinical s...
-
Article
MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK
Sorafenib is a multikinase inhibitor for the treatment of hepatocellular carcinoma. However, most patients who initially respond to sorafenib become refractory. In a previous study, we demonstrated that sphere...
-
Article
Open AccessSphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines
Cancer stem cells (CSCs) are regarded as the cause of tumor formation and recurrence. The isolation and identification of CSCs could help to develop novel therapeutic strategies specifically targeting CSCs.
